Terns Pharmaceuticals (Nasdaq: TERN), a specialist in small molecule treatments for serious diseases, is to raise $150 million via a public offering.
The company plans to use the proceeds from the offering to support research and development of its key product candidates, including TERN-701, TERN-601, and the TERN-800 series, as well as for general corporate purposes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze